MedTrace Logo

Informing Pain Treatment Using Pharmacogenomic Analysis

NCT06511401 · Status: RECRUITING · Phase: NA · Type: INTERVENTIONAL · Enrollment: 800

Last updated 2026-05-04

No results posted yet for this study

Summary

This is a randomized, prospective study to evaluate the effects of preemptive pharmacogenomic (PGx) testing on opioid dosing decisions/selections and pain score in cancer patients.

Conditions

  • Adult Patients Who Are Receiving Oncologic Care

Interventions

OTHER

Pharmacogenomic (PGx) results.

These results are designed to provide specific dosing information based on the participant's unique genetics/genomics.

Sponsors & Collaborators

  • National Human Genome Research Institute (NHGRI)

    collaborator NIH

  • University of Chicago

    lead OTHER

Principal Investigators

  • Peter H O'Donnell · University of Chicago

Study Design

Allocation
RANDOMIZED
Purpose
SUPPORTIVE_CARE
Masking
SINGLE
Model
PARALLEL

Eligibility

Min Age
18 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2024-07-30
Primary Completion
2028-01-07
Completion
2028-03-31

Countries

  • United States

Study Locations

More Related Trials

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT06511401 on ClinicalTrials.gov